e-therapeutics, a MedTech company known for integrating computational power and biological data to discover RNAi medicines, has successfully completed a £28.9 million fundraise. This fundraising effort came soon after the company delisted from the London Stock Exchange’s AIM market, where it had traded for 17 years. The proceeds from this share subscription, led by existing investors M&G Investment Management and Richard Griffiths, are expected to significantly bolster e-therapeutics’ balance sheet. CEO Ali Mortazavi has been openly critical of the UK market, describing it as ‘broken and closed’ and posing an ‘existential risk’, a sentiment which has spurred the company’s consideration of a future listing on the NASDAQ.

MedTech, Financial Services, Pharmaceuticals & Biotechnology,United Kingdom, United States

https://businesscloud.co.uk/news/e-therapeutics-eyes-nasdaq-after-raising-29m/